This microblog is for stocks that do not fit neatly in
To get started, Thomas Kelly mentioned NVIV on the “……by-hendrixnuzzles blog “:
“…. The Neuro-Spinal Scaffold is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion. The Neuro-Spinal Scaffold provides structural support to the spared spinal tissue and a supportive matrix to facilitate endogenous repair processes. It degrades over several weeks. I used the term device but in retrospect I should have used scaffold. Anyway it has now closed three days in a row at consecutive 52 week highs and it up $3.80 per share in less than a week (since the reverse split). Up now 50% in the last five weeks with many more potential catalysts until the end of May; patient updates, new patient enrollments, NASDAQ up listing to name a few. Certainly it is very high risk as are all emerging Biotechs. I agree it belongs here but I do feel it belongs. But more than anything I just wanted to inform my fellow Gummies. Long NVIVD / NVIV.
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.